Bryostatin 1

Generic Name: Bryostatin 1

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₆₈O_₁₇

CAS Number: 83314-01-6

Unique Ingredient Identifier: 37O2X55Y9E

Background: Bryostatin 1 has been investigated for the treatment of HIV Infection and Alzheimer's Disease.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Safety of Bryostatin in Patients with MS

Phase 1

Active, not recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: Bryostatin 1

First Posted Date: 2024-01-05

Last Posted Date: 2025-01-10

Lead Sponsor: Robert Fox

Target Recruit Count: 20

Registration Number: NCT06190912

Locations: 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Recurrent Melanoma
Recurrent Renal Cell Cancer
Stage IV Melanoma
Stage IV Renal Cell Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: bryostatin 1
Drug: temsirolimus

First Posted Date: 2005-06-03

Last Posted Date: 2013-05-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00112476

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Bryostatin-1 in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: bryostatin 1
Drug: chemotherapy

First Posted Date: 2004-06-23

Last Posted Date: 2013-02-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT00002725

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Bryostatin 1 in Treating Patients With Metastatic Kidney Cancer

Phase 2

Completed

Conditions: Kidney Cancer

Interventions: Drug: bryostatin 1

First Posted Date: 2004-05-03

Last Posted Date: 2013-02-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT00003968

Locations: 🇺🇸
Kimball Medical Center, Lakewood, New Jersey, United States
🇺🇸
South Jersey Hospital - Millville, Millville, New Jersey, United States
🇺🇸
Riverview Medical Center, Red Bank, New Jersey, United States

and more 14 locations

Bryostatin and Vincristine in B-Cell Malignancies

Phase 1

Completed

Conditions: Recurrent Adult Lymphoblastic Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Refractory Chronic Lymphocytic Leukemia
Refractory Multiple Myeloma
Stage III Multiple Myeloma
Recurrent Adult Immunoblastic Large Cell Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Burkitt Lymphoma
Recurrent Mantle Cell Lymphoma

Interventions: Drug: bryostatin 1
Drug: vincristine sulfate
Other: laboratory biomarker analysis

First Posted Date: 2004-03-19

Last Posted Date: 2013-01-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT00003166

Locations: 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

Bryostatin 1 in Treating Patients With Stage IV Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2003-04-23

Last Posted Date: 2013-05-30

Lead Sponsor: University of Colorado, Denver

Registration Number: NCT00003205

Locations: 🇺🇸
University of Colorado Cancer Center, Denver, Colorado, United States

Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation

Phase 2

Completed

Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Marginal Zone Lymphoma

Interventions: Drug: bryostatin 1
Drug: vincristine sulfate
Other: laboratory biomarker analysis

First Posted Date: 2003-04-09

Last Posted Date: 2013-01-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 28

Registration Number: NCT00058305

Locations: 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Primary Peritoneal Cavity Cancer
Recurrent Ovarian Epithelial Cancer
Stage III Ovarian Epithelial Cancer
Stage IV Ovarian Epithelial Cancer

Interventions: Drug: bryostatin 1
Drug: cisplatin
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 32

Registration Number: NCT00006942

Locations: 🇺🇸
City of Hope, Duarte, California, United States

Bryostatin 1 Plus Vincristine in Treating Patients With Recurrent or Refractory HIV-Related Lymphoma

Phase 1

Completed

Conditions: AIDS-related Diffuse Large Cell Lymphoma
AIDS-related Diffuse Mixed Cell Lymphoma
AIDS-related Peripheral/Systemic Lymphoma
AIDS-related Small Noncleaved Cell Lymphoma

Interventions: Drug: bryostatin 1
Drug: vincristine sulfate

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT00022555

Locations: 🇺🇸
AIDS - Associated Malignancies Clinical Trials Consortium, Rockville, Maryland, United States

Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer

Phase 2

Completed

Conditions: Recurrent Renal Cell Cancer
Stage III Renal Cell Cancer
Stage IV Renal Cell Cancer

Interventions: Biological: aldesleukin
Drug: bryostatin 1
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 65

Registration Number: NCT00032188

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy